Patient education · Men’s sexual and hormonal health

Erectile Dysfunction: Why It Can Be an Early Sign of Cardiovascular or Metabolic Disease

For many men, erectile dysfunction is the first symptom of a vascular problem that has been developing silently for years. Treating it as a plumbing inconvenience, and prescribing a tablet without asking why, misses the most useful thing it has to tell you.

The short version

Erectile dysfunction is common and increases with age. In the Massachusetts Male Aging Study, some degree of ED affected around 52% of men aged 40 to 70.
It carries an independent risk for future cardiovascular events. A meta-analysis of longitudinal studies found ED predicted cardiovascular events, myocardial infarction, cerebrovascular events and all-cause mortality, with a relative risk for cardiovascular events of roughly 1.4 to 1.5.
The effect is graded. In a prospective cohort of 95,038 Australian men aged 45 and over, more severe erectile dysfunction was associated with higher risk of cardiovascular disease hospitalisation and death.
The reason is anatomical. The penile arteries are narrower than the coronary arteries, so the same endothelial dysfunction and atherosclerosis that will eventually narrow a coronary vessel produces symptoms here first — often years earlier.
ED and cardiovascular disease share their risk factors: smoking, hypertension, dyslipidaemia, diabetes, obesity and metabolic syndrome. Endothelial dysfunction, inflammation and atherosclerosis are common mechanisms, not coincidences.
The practical consequence is that a first presentation of ED deserves a cardiovascular and metabolic assessment, not only a prescription. That assessment is inexpensive and widely available.
Not all ED is vascular. Medication effects, hormonal causes, neurological disease, pelvic surgery or radiation, and psychological factors all matter, and the evaluation should be able to tell them apart.

Why the penis is an early warning system

The tissue that produces an erection depends on arteries dilating and filling on demand. That dilation is controlled by the endothelium, the single-cell lining of every blood vessel, which releases nitric oxide in response to signals from the nervous system. Anything that damages endothelial function — smoking, high blood sugar, high blood pressure, abnormal lipids, chronic inflammation — degrades that response.

What makes this clinically useful is a matter of pipe diameter. The cavernosal arteries supplying the penis are substantially narrower than the coronary arteries. A given amount of plaque or a given degree of endothelial dysfunction therefore reduces flow through them to a symptomatic degree well before it does so in the heart. The symptom arrives first in the smaller vessel.

This is why the literature repeatedly describes erectile dysfunction as a sentinel symptom. Reviews have described arteriogenic ED as preceding a major coronary event by at least three years, and prospective studies of the association have had follow-up periods ranging from roughly four to sixteen years. The interval is the opportunity: it is time in which risk factors can be found and treated before the cardiac event occurs.

What the evidence actually shows

It predicts events independently

A meta-analysis of longitudinal studies published in Circulation: Cardiovascular Quality and Outcomes concluded that the presence of erectile dysfunction increases risk for future cardiovascular events, myocardial infarction, cerebrovascular events and all-cause mortality, with a trend toward increased cardiovascular mortality. A later analysis reported a relative risk for cardiovascular events in men with ED of about 1.47.

“Independent” is the important word. It means the association persisted after accounting for the conventional risk factors ED shares with cardiovascular disease — so ED was contributing information those factors did not already supply. Work in the Multi-Ethnic Study of Atherosclerosis cohort examined self-reported ED as a predictor of incident coronary heart disease and cardiovascular disease in men free of such events at baseline.

More severe ED, higher risk

Banks and colleagues linked questionnaire data from 95,038 Australian men aged 45 and over to hospitalisation and death records and found that more severe erectile dysfunction was associated with higher risk of cardiovascular disease hospitalisation and all-cause mortality. A dose-response relationship of that kind is one of the standard reasons to take an association seriously rather than dismissing it as confounding.

What it does not mean

It does not mean erectile dysfunction causes heart disease. It means the two are downstream of substantially the same vascular process, and one of them announces itself earlier. It also does not mean every man with ED has occult coronary disease. What it means is that the finding is informative enough to justify looking, particularly in men at intermediate risk where conventional scoring is least decisive.

What a proper evaluation includes

The evaluation is not elaborate. Most of it is history and a handful of ordinary tests.

A cardiovascular and metabolic assessment. Blood pressure, lipids, fasting glucose or HbA1c, smoking status, weight and waist measurement, family history. This is the part most often skipped when a prescription is issued from a questionnaire alone.
A medication review. Several widely used drug classes contribute, including some antihypertensives, antidepressants and antiandrogens. Identifying a medication cause changes the treatment entirely.
Hormonal assessment where indicated. Low testosterone and erectile dysfunction are related problems that are not the same problem, and treating one does not reliably treat the other.
Onset, pattern and context. Gradual onset with progressive loss of night-time and early-morning erections points toward an organic vascular cause. Sudden onset, situational variation and preserved spontaneous erections point elsewhere. Both can coexist.
Psychological and relationship factors, which are not a diagnosis of exclusion and not less real than a vascular cause.

If you are offered treatment for erectile dysfunction without anyone measuring your blood pressure or checking your glucose and lipids, you are being sold a symptom fix. That may still be what you want. It is worth knowing that is what it is.

One safety point that is not optional

Nitrates and PDE5 inhibitors must not be combined. Nitrate medicines — including nitroglycerin in any form, isosorbide preparations, and the recreational nitrites sometimes called poppers — taken with sildenafil, tadalafil, vardenafil or avanafil can cause a profound and dangerous fall in blood pressure. This contraindication is absolute and is the single most important thing to disclose before any ED prescription.

This is also a reason not to obtain these medicines outside a clinical relationship. The interaction is not obscure, but it only protects you if somebody knows both halves of your medication list.

Sorting out the cause before choosing a treatment

Erectile dysfunction is a symptom with several distinct mechanisms, and they are not treated the same way. A short, structured history separates most of them, which is why the history is worth more than any single test.

Vascular

Gradual onset over months to years, progressive, present in most situations, with loss of spontaneous night-time and early-morning erections. This is the pattern that carries the cardiovascular significance described above. It is also the pattern most likely to respond to treating the underlying risk factors, not only to a tablet.

Neurological

Diabetes of long duration, spinal injury, multiple sclerosis, and pelvic surgery or radiation — particularly prostate surgery — can damage the nerve supply directly. Onset is often abrupt and tied to a specific event, and the vascular supply may be intact.

Hormonal

Low testosterone reduces desire more consistently than it impairs erection. That distinction matters, because treating a low testosterone level in a man whose main problem is vascular will disappoint everyone. Thyroid disease and elevated prolactin are less common but worth excluding when the picture fits.

Medication-related

Several widely used drug classes contribute, including some antihypertensives, several antidepressants, antiandrogens used in prostate cancer, and heavy alcohol use. A careful medication review is free, fast, and occasionally solves the entire problem by substitution.

Psychological and relational

Sudden onset, marked variation by situation or partner, and preserved spontaneous erections point here. This is not a diagnosis of exclusion and it is not less real than a blocked artery. It also frequently coexists with an organic cause: a man with early vascular disease may develop performance anxiety on top of it, and treating only one half leaves him unwell.

The reason to sort this out first is simple. A PDE5 inhibitor may work regardless of mechanism, so a good response to a tablet tells you very little about the cause — and if the cause was vascular, the tablet has treated the symptom while the artery disease that produced it continues unexamined.

What the numbers do and do not license you to conclude

It is worth being careful with relative risk, because it is routinely oversold in both directions.

A relative risk of roughly 1.4 to 1.5 for cardiovascular events means men with erectile dysfunction had around 40 to 50 percent more events than men without it over the follow-up periods studied. It does not mean a 40 to 50 percent chance of having an event. Your absolute risk depends on your age, blood pressure, lipids, smoking status and diabetes status, and for many men the absolute numbers remain modest.

What makes the finding useful is not the size of the relative risk but where it applies. Conventional risk scoring is least decisive in the intermediate-risk range — men who are neither clearly low risk nor obviously high risk. That is exactly the group in whom an additional independent marker changes management, because it can move someone across a treatment threshold.

The follow-up periods in the underlying studies ranged from roughly four to sixteen years. That interval is the entire practical point: it is time in which blood pressure can be controlled, lipids treated, diabetes identified and smoking stopped. The symptom is only valuable if somebody acts on it.

Two further honest caveats. Erectile dysfunction is self-reported, and self-report is imperfect. And an association, even a graded and independent one, is not proof that treating the erectile dysfunction changes cardiovascular outcomes — no one has shown that. What the evidence supports is using the symptom as a prompt to assess and treat the shared risk factors, which are independently worth treating.

The treatment ladder, and where the evidence is strongest

Knowing the cause shapes the order in which treatments are tried. The ladder below is roughly the order of established evidence, not the order of marketing spend, and the two are close to inverted.

First: modify what is driving it

Stopping smoking, treating hypertension and dyslipidaemia, controlling diabetes, reducing alcohol, losing weight where relevant, and reviewing contributing medications. This is unglamorous, it is slow, and it is the only tier that treats the disease rather than the symptom. It is also the tier that acts on the cardiovascular risk the symptom was signalling.

Second: PDE5 inhibitors

Sildenafil, tadalafil, vardenafil and avanafil are the established first-line drug treatment, with a large evidence base. They differ mainly in onset and duration rather than in whether they work. They require sexual stimulation to have an effect — a point that causes avoidable disappointment when it is not explained. A meaningful proportion of apparent non-response turns out to be an inadequate dose, too few attempts, or an expectation mismatch rather than true failure.

Third: other established options

Vacuum erection devices, intraurethral alprostadil and intracavernosal injection therapy all have established places, and penile prosthesis surgery has high satisfaction rates in appropriately selected men who have not responded to less invasive options. These are not last resorts in any pejorative sense; for some men they are the right answer earlier than they are usually offered.

Where the marketed treatments sit

Low-intensity shockwave therapy, platelet-rich plasma and stem-cell preparations occupy a different tier entirely. The American Urological Association classifies shockwave therapy and intracavernosal stem cell therapy as investigational and platelet-rich plasma as experimental. They are advertised far more heavily than the treatments above, and they are supported by far less evidence. Each has its own page here.

If a clinic proposes starting at that tier without having assessed your cardiovascular and metabolic risk or trialled anything established, it is worth asking why.

Talking about it, and why most men do not

Erectile dysfunction is one of the most under-reported symptoms in general practice, and the reasons are worth naming because they are the reasons the cardiovascular signal so often goes unread.

Men commonly assume it is an inevitable consequence of ageing, that nothing can be done, or that raising it will be embarrassing for both parties. Some assume a partner will interpret it as a loss of interest, which turns a medical symptom into a relationship problem before anyone has examined the cause. Others have already tried a tablet obtained without a prescription, found it disappointing, and concluded the matter is closed.

Clinicians contribute to the silence too. It is rarely on a standard review-of-systems checklist, appointment time is short, and a symptom the patient does not volunteer often goes unasked. The result is that a marker with a documented four-to-sixteen-year lead over cardiovascular events sits unmentioned in exactly the population it would be most useful in.

If it helps to have a script: “I have been having trouble with erections, and I have read it can be an early sign of blood-vessel or metabolic problems. Can we check that side of things?” That sentence reframes the visit from an embarrassing request into a risk assessment, which is what it should have been. It also makes it much harder for the consultation to end with a prescription and nothing else.

Partners can raise it too. A change of this kind is frequently noticed before it is discussed, and framing it as a health question rather than a relationship question is usually accurate as well as kinder.

What it costs, and what insurance usually will not cover

We publish cost bands rather than prices. Prices vary by region, practice and contract, and a specific figure printed on a web page is wrong within months. Ask any practice for a written quotation before agreeing to treatment.

Typical band. An initial evaluation is an ordinary clinician visit with routine laboratory testing. Generic PDE5 inhibitors are inexpensive; branded versions are not. The evaluation is generally the cheapest and most informative part of the whole pathway.

What the band usually excludes. The visit and medication bands exclude specialist referral, vascular imaging where indicated, cardiology assessment if the risk assessment prompts it, and any treatment for the underlying conditions found.

Coverage. Evaluation of erectile dysfunction and management of the cardiovascular and metabolic conditions it uncovers are ordinary medical care and are generally covered like any other. Coverage of ED medication itself varies considerably and quantity limits are common. Where a treatment is characterised as lifestyle or cosmetic rather than medical, coverage is frequently excluded; where a treatment is characterised as lifestyle rather than medical, coverage is frequently excluded.

On cheaper routes. Treatment obtained abroad, products bought online outside a licensed pharmacy, and procedures performed by unlicensed providers are all cheaper. We describe that these routes exist and why we do not guide readers to them. We do not publish sourcing instructions for them.

Not yet availableLifecycle: PROPOSED · reviewed monthly · last reviewed 2026-08-15

In development

Nothing in this section is available to you now. It is here so you can recognise the names when you meet them, not so you can seek them out.

Regenerative approaches — shockwave therapy, platelet-rich plasma and stem-cell preparations — are the most heavily marketed emerging treatments in this area and are addressed on their own pages, because their guideline status is investigational or experimental rather than established. Ongoing trials continue in each. A treatment being studied, and a treatment being ready, are different things.